Figure 1.

FXR activation inhibits prostate cancer cell proliferation. (A) LNcaP cells were treated with CDCA (5 μM), GW4064 (2 μM) or vehicle control (DMSO) and cell proliferation ability was measured using BrdU assays. A₄₅₀ absorption was assayed following treatment for 24 h. (B) Western blot analysis showing FXR protein expression in the LNcaP cells transfected with siRNA oligos targeting FXR or a negative control. (C) LNcaP cells were pre-transfected with siRNA oligos targeting FXR or negative controls for 24 hr, and then treated with CDCA, GW4064 or vehicle control (DMSO) for BrdU cell proliferation assays. FXR, farnesoid X receptor; DMSO, dimethyl sulfoxide; CDCA, chenodeoxycholic acid; BrdU, bromodeoxyuridine; NC, negative control.